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Background/Aims: Host factors that may influence progression of hepatitis C infection to chronic hepatitis include
T-cell responses and iron accumulation. We evaluated the hepatic expression of immunological markers relevant for a
cytotoxic response in relation to viral and HFE genotype.
Methods: Frozen liver biopsies were obtained at diagnosis from 28 HFE genotyped patients. Sections stained for CD8,
MHC-I, b2m, HFE and CD68 were analyzed blind by morphometry. Response to therapy was available in 12 cases.
Results: A negative correlation was found between the number of CD81 cells and fibrosis. CD81 cells localized as
clusters in portal tracts and sinusoids and were seen interacting with MHC-I positive lining cells. MHC-I and b2m were
expressed mainly in the endothelial and Kupffer cells. HFE was expressed in most, but not all, round and dendritic
CD681 cells. Patients with virus genotype 3a had higher hepatic MHC-I and HFE expression, and a better-sustained
response to IFN therapy than other patients.
Conclusions: In chronic hepatitis C virus infection MHC-I expression in the liver seems to relate to viral-genotype. In
addition, the expression of MHC-I molecules by Kupffer cells places them as probable important players in the host
response to HCV.
q 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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1. Introduction
The hepatitis C virus (HCV) genotypes differ in world
distribution and in resistance to IFN therapy [1]. The
reasons for the differences in response to IFN are unclear.
Possible modifiers include hepatic iron [2–7] and T-cell
(CD8þ) reactivity against the hepatitis C virus [8–12].
A significant negative correlation between hepatic iron
overload and the number of circulating and hepatic CD8þ
cells was reported in hereditary hemochromatosis (HH)
patients homozygous for the C282Y HFE mutation [13].
HFE mutations may influence the course and outcome of
chronic hepatitis C by affecting iron loading [14–19]. Since
HFE is a non-classical MHC-I protein, it could affect host
response to the virus and disease progression.
In this paper we examine the quantitative distribution of
CD8þ cells and other immunological markers relevant to a T
CD8þ host response by morphometry in liver biopsies from
HFE and HCV genotyped patients with chronic hepatitis.
2. Patients and methods
2.1. Study design
Liver biopsies were prepared in the immunohistochemistry lab
for the following markers: CD8, MHC-I, b2m, HFE and CD68. The
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immunochemistry analysis was ‘closed’ when 30 biopsies were completed.
The stained sections were seen ‘blind’ by two observers for the qualitative
and quantitative assessment of the tissue distribution of the markers without
knowledge of the patients’ identity. The latter was only disclosed after the
immunohistochemistry study was concluded. Correlations between histo-
pathological and clinical parameters, HFE and HCV genotype were done.
An analysis of response to therapy was possible in 12 cases (see Section
2.4). Six liver biopsies from C282Y homozygous patients, not infected with
HCV, were used as controls.
Informed consent in writing was obtained from all patients. The
protocol conformed to the ethical guidelines of the Helsinki Declaration of
1975. Chronic hepatitis C virus infection was diagnosed and treatment was
implemented according to published guidelines [1]. Exclusion criteria were
other viral hepatitis, autoimmune hepatitis, secondary causes of iron
overload, and history of alcohol consumption one year before liver biopsy
(men .60 g/day; women .40 g/day) (Table 1). Two cases had to be
excluded for insufficient information.
2.2. Hepatitis C virus genotyping
Anti-HCV antibodies were detected by a commercial enzyme-linked
immunosorbent assay (HCV 3rd generation ELISA and EIA, Ghent,
Belgium) and by the 3rd generation recombinant immunoblot assay (RIBA,
Inno-Lia, Ghent, Belgium) and confirmed by testing for HCV RNA using a
reverse transcription polymerase chain reaction (Amplicor, HCV, Roche
Diagnostic Systems, Basel, Switzerland). HCV genotypes were determined
by the Inno-LiPA HCV II assay (Innogenetics, Bayer, Ghent, Belgium).
2.3. Treatment
Criteria for treatment were based on histological and biochemical
parameters (ALT . 40U/l) and PCR-RNA viral positive. Patients were
treated with IFN-a (2a or 2b) 3 MU 3 times/week plus ribavirin 1 or
1.2 g/day (before October/2001) and after this date IFN-a Peguilated (2a or
2b) plus ribavirin. Genotype 1 and 4 patients were treated for 12 months,
genotype 2 and 3 for 6 months (except before 1999 when patients with
genotype 3a were also treated for 12 months).
2.4. Response to treatment
A positive treatment response was considered when a viral RNA
negative test was detected by PCR, 6 months after the treatment was
completed. Patients were followed up every 6 months. When patient
identity was disclosed, it became apparent that 12 HFE and HCV genotyped
patients had completed therapy one year before. A sustained response was
observed in six patients. The other six were considered non-responders: five
with HCV RNA detectable and ALT which failed to decrease throughout
treatment; in one patient a complete virological and biochemical response
was observed at the end of treatment, followed by re-emergence of the virus
during the follow-up period.
2.5. Liver histopathology
Formalin-fixed paraffin-embedded liver biopsies were analyzed for
siderosis, fibrosis, steatosis and necroinflammatory activity by one
pathologist (Table 1). Hepatic iron concentration (HIC) was determined
by atomic absorption in fresh biopsies or from formalin-fixed paraffin-
embedded biopsies [20]. Hepatic iron index (HII) was calculated by
dividing HIC (mmol/g of dry weight) by the patients’ age (years).
2.6. Biochemical serum parameters
Fasting serum iron, total iron binding capacity, serum ferritin, ALT and
AST were determined by standard assays, at the time of liver biopsy.
2.7. HFE genotyping
HFE gene genotyping was done using the ‘Haemochromatosis Gene
Mutation Assay’ (Vienna Lab, Vienna, Austria), according to the
manufacturer’s specifications [21] as described [22].
2.8. Antibodies
Monoclonal antibodies (mAb) against the macrophage marker CD68
(KP1), the T-cell marker CD8 (C8/144B) and MHC-I (W6/32) were
obtained from DAKO (Glostrup, Denmark). HFE mAb (2F5) was prepared
by Ehrlich and collaborators [23]. b2microglobulin was identified by an
anti-b2m mAb (TÜ99, BD PharMingen, Europe BD Biosciences, Belgium).
Mouse mAbs DAK-GO1 (DAKO) and G155-228 (BD PharMingen), IgG
and IgM, respectively, were used as negative controls. The antibody
specificity of DAK-GO1 is directed towards Aspergillus niger glucose
oxidase, an enzyme which is neither present nor inducible in mammalian
tissues. G155-228 is specific for trinitrophenol, a hapten not expressed on
human cells.
For immunofluorescence an anti-mouse Alexa 488-labelled secondary
antibody was used. For signal amplification, the tyramide signal
amplification (TSA)e Kit (Alexa Fluor 568, Molecular Probes, Leiden,
The Netherlands) was used. This Kit contained a HRP-conjugated
secondary antibody and Alexa 568-labeled tyramide.
For immunohistochemistry rabbit anti-mouse immunoglobulins and
APAAP conjugate were used (DAKO).
2.9. Immunohistochemistry
Cryostat sections or formalin-fixed, paraffin-embedded sections, 6 mm
thick, were mounted on gelatin covered glass slides and dried overnight.
Cryostat sections were fixed in acetone for 10 min, dried, wrapped in
aluminum foil and stored at 220 8C until used. Slides were allowed to
come to room temperature (RT) before immunohistochemical staining.
Formalin-fixed paraffin-embedded sections were prepared as described in
Ref. [13]. All sections were stained using the APAAP method. Cryostat
sections were incubated for 30 min with the mAbs: 2F5 at dilution 1:6000,
KP1 1:6000, W6/32 1:200, TÜ99 1:100; paraffin sections—overnight with
C8/144B mAb at 1:200.
2.10. Double immunofluorescence
Double immunofluorescence was used to identify Kupffer cells positive
for HFE and/or CD68. Detection of two primary mAbs raised in the same
species (mouse, in this case) was performed by sequential tyramide signal
amplification and conventional fluorescence detection (dilutional neglect)
method [24]. All steps were performed at RT. Acetone-fixed cryostat
sections were incubated in phosphate-buffer saline with H2O2 0.3% for
5 min, in the dark in order to quench endogenous peroxidase activity. Then,
the specimens were blocked with 1% Blocking Reagent (TSA Kit) for
60 min. Tissues were labeled with the first primary antibody (2F5) diluted
in 1% blocking reagent, for 60 min. After washing, the HRP-conjugated
secondary antibody was applied at a 1:100 dilution, and incubated for
60 min. Additional washes were followed by the application on the
specimen of the tyramide working solution at a 1:50 dilution. Finally, the
second primary antibody (anti-CD68) was applied and incubated for
60 min, and subsequently, the Alexa 488-conjugated secondary antibody at
a 1:2000 dilution (Molecular Probes) also for 60 min. Sections were
mounted in Vectastain with DAPI (Vector Laboratories, Burlingame, CA)
and analyzed in a Axioskop microscope (Zeiss, Göttingen, Germany)
equipped with a SPOT II (Diagnostic Instruments, Sterling, Michigan)
camera.
Stainings with TSA method using the standard (normal dilution used
without TSA), 2 £ , 4 £ and 8 £ higher dilutions of the conventionally
used primary antibody dilution were done. Thus, the dilution of the first
primary antibody, which was consistently not recognized by a conventional
Alexa 488-labeled secondary antibody, but was still clearly detectable by a
simple fluorescent amplification method, was chosen. As controls, sections
were also immunostained for either antigen separately.
Negative controls included incubations with DAK-GO1and leaving out
the primary or secondary antibodies.
2.11. Morphometric microscopy analysis
2.11.1. CD68þ and HFEþ cells
Alternate sections were stained for CD68 or HFE. The positive cells in
the two serial sections were counted by conventional microscopic analysis.
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Table 1
Clinical characteristics of patients with chronic hepatitis C virus
Patient Sex Agea
(yr)
HFE genotype HCV genotype Viral loadb
(UI/ml) £ 106








Fib Sid Ste Inf
1 F 31 C282Y/H63D 1a 0.36 64 41 216 53 13 0 0 0 1 19 0.61 NR
2 F 32 wt/H63D NA NA NA NA NA NA NA 1 0 1 1 26 0.81 –
3 F 35 wt/wt 1a 0.39 114 57 99 32 150 1 0 1 1 5 0.14 –
4 F 38 wt/H63D 3a 1.70 48 32 222 96 273 1 2 1 1 28 0.74 –
5 F 41 wt/wt 3a 0.10 52 27 115 32 45 1 0 1 1 58 1.41 SR
6 F 50 wt/wt 3a 0.21 43 38 NA NA 91 1 0 1 1 15 0.30 SR
7 F 60 wt/H63D 1b 0.85 50 38 89 28 85 0 0 0 1 14 0.23 –
8 F 63 wt/H63D 1b 0.54 67 66 94 30 73 1 0 0 2 10 0.16 NR*
9 M 29 wt/H63D 1a NA 432 281 99 30 475 1 1 1 1 20 0.69 –
10 M 30 wt/wt 1a 2.28 84 39 123 43 290 1 0 0 1 15 0.50 –
11 M 30 wt/wt NA NA 219 78 117 42 NA 1 0 1 2 23 0.77 –
12 M 31 wt/wt 3a NA 45 16 125 47 98 1 0 1 2 24 0.77 SR
13 M 31 wt/H63D 3a NA 250 74 61 22 73 0 0 2 2 11 0.35 –
14 M 33 wt/H63D 1a 0.01 39 32 114 51 228 0 0 0 1 31 0.94 –
15 M 35 wt/H63D 3a 1.49 155 69 186 58 383 1 0 3 1 16 0.46 SR
16 M 35 wt/wt NA .1.00 111 62 115 27 58 1 0 0 1 9 0.26 –
17 M 37 wt/wt 4c/4d 0.29 60 46 75 25 332 1 0 0 2 72 1.94 –
18 M 40 wt/wt NA NA 49 31 91 37 96 1 0 1 1 18 0.45 SR
19 M 40 wt/wt 3a 0.30 38 39 217 61 146 1 0 0 2 14 0.35 –
20 M 42 wt/wt 3a 0.01 49 35 82 26 75 0 0 0 1 18 0.43 SR
21 M 43 C282Y/H63D 1b 1.08 NA NA NA NA NA 1 1 1 2 46 1.07 –
22 M 43 C282Y/wt 3a 0.21 75 38 238 98 214 3 1 2 1 48 1.12 –
23 M 43 wt/wt 4 .0.50 111 74 123 43 233 0 1 1 1 44 1.02 –
24 M 44 wt/wt NA 0.94 109 85 107 40 202 1 0 0 1 8 0.18 –
25 M 47 wt/wt 1b NA 58 38 103 33 NA 1 0 0 2 9 0.19 NR
26 M 47 wt/wt 1a/1b 0.48 53 47 106 29 152 2 0 0 2 11 0.23 NR
27 M 49 wt/wt 1b 0.71 83 40 79 22 544 0 1 1 1 14 0.29 NR
28 M 54 H63D/H63D 2a/2c 0.15 291 122 160 45 174 1 0 1 2 18 0.33 SR
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; F, female; Ft, ferritin; HIC, hepatic iron concentration; HII, hepatic iron index; M, male; NA, not available; NR, non-
responder; NR*, relapser; SR, sustained responder; TfSat, transferrin saturation.
a Age at diagnosis.
b Pre-treatment viral load.
c Fib, fibrosis; Sid, siderosis; Ste, steatosis; Inf, necroinflammatory activity. Siderosis was scored by Perls’ blue staining as follows: 0, no siderosis; 1, ,25% of hepatocytes affected; 2, 25–50% of hepatocytes
affected; 3, 50–70% of hepatocytes affected; 4, .75% of hepatocytes affected and Kupffer cells. Fibrosis staging was scored: 0, no fibrosis; 1, portal fibrosis without septa; 2, portal fibrosis with few septa; 3,
numerous septa without cirrhosis; 4, cirrhosis. Steatosis staging was scored: 0, no steatosis; 1, ,30% of hepatocytes affected; 2, 30–70% of hepatocytes affected; 3, .70% of hepatocytes affected. Inflammatory












































Subsequently, the same sections were evaluated by computer-assisted
image analysis. A Leica DMLB microscope (Leica Cambridge Lda.,
Cambridge, UK) equipped with a couple device color camera (3CCD) was
used to examine the sections under a £ 400 magnification. In LeicaQWin
image analyzer (Leica Cambridge, Lda.) a square image frame (with an
area of 26276.5 mm2) was used. In the first case, for each patient, 10 similar
(i.e. in the same zone of the section) microscopic fields, in randomly chosen
hepatic lobuli, were evaluated for both antibodies. The results were
expressed as the mean ^ SEM (no positive cells/mm2). Computerized
image analysis of CD68 and HFE was done using a routine developed in the
LeicaQWin program (HFE.Q5R). Threshold levels of brightness were set
and a temporary binary color image was super imposed on the digitalized
image. The areas of interest (red, stained FastRed cells) were outlined in a
pseudocolor. This permits checking the accuracy of the measured area.
Each color is a unique combination of red, green and blue (RGB) ranging
between levels of 0–255, allowing the detection of over 16 £ 106 different
colors. Thus to identify FastRed stained cells, selected RGB thresholds
(RGB: 0–170, 0–49, 0–119), were obtained. Minimum size of cells was
also identified (.4 mm). Mean positive area was expressed as mm2
(mean ^ SEM). For each biopsy 5 fields randomly chosen were analyzed.
A good correlation between conventional microscope analysis and the
computerized image analysis was obtained (HFE: r ¼ 0:632; n ¼ 15;P ¼
0:011; CD68: r ¼ 0:593; n ¼ 15;P ¼ 0:020).
2.11.2. MHC-I and b2microglobulin
MHC-I and b2m expression was evaluated using a similar routine
(MHC.Q5R), as the one for HFE and CD68, with different thresholds of
RGB (0–180, 0–91, 0–158).
2.11.3. CD8þ cells
CD8þ cells were evaluated blindly using the conventional analysis.
Intra-observer reproducibility was assessed by repeated measurement of
this parameter in selected samples ðr ¼ 0:985; n ¼ 9;P , 0:001Þ:
2.12. Statistical analysis
Pearson’s correlation coefficients were estimated to assess the relation
between two continuous variables, while Spearman’s rank correlation
coefficients were used to determine the degree of association between
two variables, when one of them was of an ordered categorical type.
Independent-samples T-test was used for statistical comparison of means
(^SD) between two independent groups. In this T-test analysis the variance
of each variable was taken in consideration using the Levene’s test for
equality of variances. Paired-samples T-test was used to compare means of
two variables for a single individual. Pearson x2 (with Yates’s correction
for 2 £ 2 tables when one cell had expected count less than 5) was used for
comparison of proportions between groups. P-values ,0.05 were
considered significant. The statistical analysis was performed using the
SPSS 11.5 software (SPSS Inc., Chicago, IL).
3. Results
3.1. Hepatic expression of immunological markers
HFE protein was evenly distributed in the liver lobuli and
was seen exclusively in non-parenchymal cells (Fig. 1B).
HFE-positive cells were characterized by an irregular round
shape or a dendritic shape, with protrusions of their
cytoplasm towards sinusoidal spaces, typical of Kupffer
cells. When an anti-CD68 mAb (a marker of Kupffer cells)
was used, a positive immunoreactivity with a similar
distribution pattern was observed (Fig. 1A). The negative
control did not show any notable immune reactivity (not
shown). However, although CD68þ cells were morphologi-
cally identical to the sinusoidal lining cells that express
HFE, in several patients the immune reactivity associated
with the CD68 protein usually displayed a more intense
staining and CD68þ cells appeared to be more numerous
than HFEþ cells. Morphometric analysis of the density of
HFEþ cells and those exhibiting CD68 staining, an index of
the Kupffer cell population, confirmed those differences: in
approximately 50% of the patients the number of CD68þ
cells/mm2 was higher than the number of HFEþ cells
(Table 2).
Double immunofluorescence, confirmed that HFE was
expressed within the Kupffer cells, defined as CD68-
positive cells. However, not all CD68-expressing cells
were positive for HFE. Interestingly, in the majority of the
cells these two proteins were in different cellular compart-
ments (Fig. 2).
MHC-I (Fig. 1C) and b2m (Fig. 1D) molecules were
expressed mainly in endothelial and Kupffer cells. MHC-I
expression was rare to occasional faint staining of
hepatocellular membranes in the majority of the patients.
Only 2 out of 27 patients showed strong ‘honeycomb’
positivity for MHC-I staining. CD8þ cells were localized in
the sinusoids and frequently as clusters in the portal tracts
(Fig. 1F).
In general, HFE expression did not differ between HCV
patients without ðn ¼ 11Þ or with any HFE mutation ðn ¼
11Þ (mean ^ SD positive cell area: 56 ^ 37 and
Fig. 1. Expression of different immunological markers in chronic HCV
infection. Liver sections from a patient with chronic hepatitis C virus
infection with a wt/wt HFE genotype stained using the APAAPmethod,
and FastRed substrate A–E, cryostat sections; F, formalin-fixed
paraffin-embedded section. CD681 (A) and HFE1 (B) cells had a
typical pattern of Kupffer cells, although the expression of HFE was
less intense and abundant. MHC-I (C, E) and b2m (D) molecules were
expressed in endothelial and Kupffer cells. In E, a mononuclear cell
(arrow) that is in close contact with a sinusoidal cell is also shown to be
MHC-I positive. CD81 cells (F) were found in the sinusoids.
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42 ^ 32 mm2, respectively, P ¼ 0:369). However, the one
compound heterozygous (Patient #21, Table 1) and the only
H63D homozygous (Patient #28, Table 1) had very low
(7.1 mm2) and null HFE expression, respectively. No HFE
protein was expressed in the C282Y HH liver biopsies. The
presence of any HFE mutation had no impact on the
expression of all the other immunological markers analyzed
(not shown).
3.2. Immunological markers, viral genotype, viral load and
iron biochemistry
MHC-I expression in liver lobuli in biopsies from
patients infected with HCV3a genotype (mean ^ SD:
173 ^ 105 mm2, n ¼ 8) was significantly higher ðP ¼
0:006Þ than in patients with other viral genotype
(32 ^ 35 mm2, n ¼ 13; Fig. 3), and similar to the MHC-I
expression in HH patients (207 ^ 79 mm2, n ¼ 6; Fig. 3).
HFE expression followed the MHC-I pattern in HCV
patients: 3a genotype patients had significantly higher ðP ¼
0:036Þ HFE expression (mean ^ SD: 61 ^ 32 mm2, n ¼ 7)
than patients infected with other viral genotypes
(30 ^ 22 mm2, n ¼ 10). Expression of CD68, b2m and the
number of CD8þ cells were not associated with virus
genotype. None of the immunological markers studied was
associated with viral load (not shown).
There was a negative correlation between the number
of CD8þ cells in the liver lobuli and the grade of fibrosis
ðr ¼ 20:514; n ¼ 19;P ¼ 0:024Þ: In addition, the expres-
sion of CD68 correlated positively with serum iron ðr ¼
0:459; n ¼ 19;P ¼ 0:048Þ and the expression of MHC-I
correlated positively with HIC ðr ¼ 0:669; n ¼ 26;P ,
0:001Þ; HII ðr ¼ 0:667; n ¼ 26;P , 0:001Þ; and transferrin
saturation ðr ¼ 0:486; n ¼ 23;P ¼ 0:019Þ: No differences in
hepatic iron load levels were seen between viral genotypes.
3.3. Response to interferon treatment
Virus genotype was strongly associated with response
to IFN treatment ðP ¼ 0:019Þ: Five out of 6 patients with a
sustained response had the 3a genotype (one had the 2a/2b
genotype), while the non-responders had all the 1a or 1b
genotype. Sustained responders had significantly higher
levels of MHC-I (mean ^ SD: 137 ^ 111 mm2, n ¼ 6)
than non-responders (14 ^ 8 mm2, n ¼ 6;P ¼ 0:042;
Fig. 4).
4. Discussion
The starting purpose of the present study with basis on
earlier work on HH [13] was to examine whether markers
relevant to the development of a cytotoxic response were
altered and/or related to hepatic iron load in patients with
chronic HCV. The work focused on MHC-I, b2m, HFE and
Table 2
Comparative morphometrical analysis of HFEþ and CD68þ cells in
patients with chronic hepatitis C
Group n CD68a HFEa
CD68 . HFE† 7 552 ^ 68 300 ^ 92
CD68 ¼ HFE 8 463 ^ 84 480 ^ 119
CD68 , HFE‡ 1 601 750
n, number of patients, †P , 0:001; ‡P , 0:0001; paired-samples T-test.
a Mean ^ SD.
Fig. 2. Double immunofluorescent staining of CD68 and HFE
molecules. Representative human liver section from a patient with
chronic hepatitis C incubated with anti-CD68 (A) anti-HFE (B)
monoclonal antibodies, detected with an Alexa 488-conjugated
secondary antibody (green) and using the Tyramide Signal Amplifica-
tion method with an HRP-conjugated secondary antibody and an Alexa
568-labelled tyramide (red), respectively. In (C) photos (A) and (B)
were merged, demonstrating that these two proteins do not co-localize.
The arrow indicates a Kupffer cell that is HFE negative (original
magnification 3 630).
Fig. 3. Impact of HCV genotype on classical MHC-I expression.
Sections from patients with chronic hepatitis C virus infection with 3a
genotype had a significantly higher MHC-I expression (mean 6 SD:
173 6 105 mm2, n5 8) than those infected with other viral genotypes
(32 6 35 mm2, n5 13;P5 0:006; T-test). Insert shows two frozen liver
sections stained for MHC-I with the W6/32 mAb, using the APAAP
method and FastRed substrate, representative of a patient with 3a
genotype and high MHC-I expression (upper figure) and a patient with
1b genotype and low MHC-I expression (lower figure). Shaded area:
mean 6 SD of MHC morphometry in liver biopsies from HH C282Y
homozygous patients.
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numbers of intra-hepatic CD8þ cells. CD68 was used as a
marker of Kupffer cells. A negative correlation was found
between the number of CD8þ cells and development of
fibrosis confirming a recent report [12]. CD8þ cells were
localized as clusters in the portal tracts and in sinusoids. In
the sinusoids, positive cells were frequently seen interacting
with MHC-I positive lining cells. MHC-I and b2m
molecules were expressed mainly in the endothelial and
Kupffer cells. Kupffer cells in chronic HCV have a
phenotype of professional antigen presenting cells [25].
Their capacity to phagocytose infected hepatocytes and
serum viral-antibody coated particles, together with their
close contact with CD8þ cells, both in sinusoids and in
portal tracts, place them as possible important players in the
host response against the viral infection. Although no
correlation was seen between the level of MHC-I expression
and the number of CD8þ lymphocytes, the possibility that a
stronger specific CD8þ T-cell response occurs in the
patients with higher MHC-I expression is attractive. The
finding of much higher levels of MHC-I expression in 3a
genotype patients may offer a molecular and immunological
basis for the clinical experience reported by others [26].
This finding is in agreement with the earlier finding of a
higher cytotoxic response in HCV3a genotype patients [27].
The results confirm that HFE is expressed in round and
dendritic shaped cells, in CD68þ Kupffer cells [28,29].
Interestingly, not all CD68þ cells express HFE. This may
indicate the existence of Kupffer cells in different metabolic
states or that HFE identifies different subpopulations of
Kupffer cells. The lowest levels of HFE expression were
seen in a compound heterozygous for the two most common
HFE mutations and in a liver biopsy from an H63D
homozygous, suggesting contrary to current belief [30] that
both mutations may affect HFE expression. In two recent
studies of the rat HFE gene expression, others have found
HFE in hepatocytes [31,32]. No immunohistochemistry data
were presented in those studies. The present and earlier
observations of Bastin et al. [28], were made in human liver
biopsies. The differences reported may reflect differences in
the species studied, in the detection methods, or the
antibodies used.
The most significant observation of the present study,
however, regards the measurement by morphometry of
much higher levels of MHC-I expression in 3a genotype
patients. The observation that HFE expression followed
the same pattern of quantitative expression as that of
classical MHC-I may indicate that a link may exist
between the non-classical and the classical MHC-I
molecules at the cellular level. Linkage disequilibrium
between HLA-A alleles and HFE mutations has been
reported previously [33].
Two possible explanations can be envisaged for the
association with viral genotype. HCV viruses type 1 down-
regulate MHC-I and HFE expression, similarly to reported
findings with other viral proteins [23,34]. This explanation is
supported by the recent finding of Konan et al., showing that
the non-structural protein precursor NS4A/B from HCV 1b
genotype reduces MHC-I cell surface presentation, by
inhibiting global ER-to-Golgi traffic [35]. Two other studies
showed that HCV virus might affect MHC-I expression [36,
37]. These studies were done in vitro. It is of considerable
interest that we now observe comparable differences in the
expression of MHC-I in Kupffer cells and in endothelial cells
in liver biopsies. A second explanation may relate to the
finding that the major envelope protein of HCV (E2) of HCV-
3a does not bind CD81 [38].
The statistically significant correlation between some
iron parameters and MHC-I expression is of interest in the
light of other emerging connections between iron load and
MHC-I in mice [39].
In conclusion, the present study reinforces the evidence
for the complexity of host–pathogen interactions taking
place in the development of a chronic viral infection. The
results also point to Kupffer cells and MHC-I as important
players in the process.
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Fig. 4. Impact of MHC-I expression in the response to IFN therapy.
Patients with chronic hepatitis C with a sustained response (SR) to IFN
therapy had significantly higher expression of classical MHC-I
molecules in the liver (mean 6 SD: 137 6 111 mm2, n5 6) than non-
responders (NR) (14 6 6 mm2, n5 8;P5 0:042; T-test). See text for
viral genotype of the SR and NR. Shaded area: mean 6 SD of
MHC morphometry in liver biopsies from HH C282Y homozygous
patients.
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